Efficacy Study of Rapamycin- and Zotarolimus-Eluting Stents to Reduce Coronary Restenosis - Related Studies

Efficacy Study of Rapamycin- and Zotarolimus-Eluting Stents to Reduce Coronary Restenosis (ISAR-TEST-5)

This study is currently recruiting participants.

Study NCT00598533. Last updated on March 13, 2008. Information provided by Deutsches Herzzentrum Muenchen

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Coronary Heart Disease

2	Additional conditions recognized in this trial
		Coronary Disease
		Coronary Restenosis
		Heart Diseases

3	More general conditions related to this trial
		Cardiovascular Diseases
		Coronary Stenosis
		Myocardial Ischemia
		Vascular Diseases

4	Additional drug interventions recognized in this trial
		Probucol
		Sirolimus

5	More general drug interventions related to this trial
		Anti-Bacterial Agents
		Anti-Infective Agents
		Antibiotics, Antineoplastic
		Anticholesteremic Agents
		Antifungal Agents
		Antilipemic Agents
		Antimetabolites
		Antineoplastic Agents
		Antioxidants
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Protective Agents
		Therapeutic Uses

6	Sponsors listed in this trial
		Deutsches Herzzentrum Muenchen